VIENNA, Va., Oct. 29 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (AMEX:CVM) announced today that it has published a very comprehensive review of cancer immunotherapies on its new website. The link is located in the top right hand corner of its home page at http://www.cel-sci.com/ .
Geert Kersten, Chief Executive Officer of CEL-SCI said, "Immunotherapy in the minds of many represents the future of cancer therapy. We have created an easy to navigate, interactive web based review that is designed to be helpful to doctors, patients as well as investors." CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R). In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine as a neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.
The Company has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense. DATASOURCE: CEL-SCI Corporation CONTACT: Gavin de Windt of CEL-SCI Corporation, +1-703-506-9460, Fax, +1-703-506-9471 Web site: http://www.cel-sci.com/
|